Novo Nordisk Valuation
Is NOVO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NOVO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NOVO B (DKK908.3) is trading below our estimate of fair value (DKK997.48)
Significantly Below Fair Value: NOVO B is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NOVO B?
Other financial metrics that can be useful for relative valuation.
What is NOVO B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | DKK 4.03t |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 15.6x |
Enterprise Value/EBITDA | 31.8x |
PEG Ratio | 3.1x |
Price to Earnings Ratio vs Peers
How does NOVO B's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 55.6x | ||
HLUN B H. Lundbeck | 17.9x | 9.8% | DKK 42.2b |
ALK B ALK-Abelló | 64.3x | 19.5% | DKK 35.7b |
LLY Eli Lilly | 116.5x | 28.9% | US$830.0b |
JNJ Johnson & Johnson | 23.5x | 7.1% | US$384.3b |
NOVO B Novo Nordisk | 44.8x | 14.4% | DKK 4.0t |
Price-To-Earnings vs Peers: NOVO B is good value based on its Price-To-Earnings Ratio (44.8x) compared to the peer average (55.6x).
Price to Earnings Ratio vs Industry
How does NOVO B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: NOVO B is expensive based on its Price-To-Earnings Ratio (44.8x) compared to the European Pharmaceuticals industry average (23.6x).
Price to Earnings Ratio vs Fair Ratio
What is NOVO B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 44.8x |
Fair PE Ratio | 53.9x |
Price-To-Earnings vs Fair Ratio: NOVO B is good value based on its Price-To-Earnings Ratio (44.8x) compared to the estimated Fair Price-To-Earnings Ratio (53.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | DKK 908.30 | DKK 965.52 +6.3% | 18.9% | DKK 1,200.00 | DKK 560.00 | n/a | 25 |
Aug ’25 | DKK 915.80 | DKK 967.56 +5.7% | 19.0% | DKK 1,200.00 | DKK 560.00 | n/a | 25 |
Jul ’25 | DKK 1,004.60 | DKK 952.15 -5.2% | 18.3% | DKK 1,200.00 | DKK 560.00 | n/a | 26 |
Jun ’25 | DKK 927.30 | DKK 917.31 -1.1% | 18.5% | DKK 1,120.00 | DKK 530.00 | n/a | 26 |
May ’25 | DKK 897.70 | DKK 904.20 +0.7% | 19.4% | DKK 1,120.00 | DKK 530.00 | n/a | 25 |
Apr ’25 | DKK 881.30 | DKK 894.24 +1.5% | 19.6% | DKK 1,120.00 | DKK 530.00 | n/a | 25 |
Mar ’25 | DKK 850.90 | DKK 785.08 -7.7% | 24.1% | DKK 975.00 | DKK 140.00 | n/a | 24 |
Feb ’25 | DKK 786.40 | DKK 737.84 -6.2% | 24.7% | DKK 950.00 | DKK 140.00 | n/a | 24 |
Jan ’25 | DKK 698.10 | DKK 689.43 -1.2% | 27.4% | DKK 875.00 | DKK 120.00 | n/a | 23 |
Dec ’24 | DKK 698.70 | DKK 680.04 -2.7% | 27.2% | DKK 875.00 | DKK 120.00 | n/a | 23 |
Nov ’24 | DKK 687.70 | DKK 683.48 -0.6% | 21.1% | DKK 825.00 | DKK 360.00 | n/a | 22 |
Oct ’24 | DKK 643.90 | DKK 648.75 +0.8% | 19.7% | DKK 810.00 | DKK 360.00 | n/a | 22 |
Sep ’24 | DKK 650.60 | DKK 618.30 -5.0% | 18.1% | DKK 775.00 | DKK 360.00 | n/a | 22 |
Aug ’24 | DKK 550.10 | DKK 583.13 +6.0% | 15.8% | DKK 725.00 | DKK 360.00 | DKK 915.80 | 23 |
Jul ’24 | DKK 549.70 | DKK 579.06 +5.3% | 16.2% | DKK 725.00 | DKK 360.00 | DKK 1,004.60 | 22 |
Jun ’24 | DKK 549.30 | DKK 574.51 +4.6% | 16.8% | DKK 725.00 | DKK 360.00 | DKK 927.30 | 22 |
May ’24 | DKK 565.40 | DKK 559.05 -1.1% | 19.5% | DKK 725.00 | DKK 340.00 | DKK 897.70 | 22 |
Apr ’24 | DKK 542.90 | DKK 510.61 -5.9% | 18.6% | DKK 620.00 | DKK 340.00 | DKK 881.30 | 22 |
Mar ’24 | DKK 498.90 | DKK 489.63 -1.9% | 17.0% | DKK 610.00 | DKK 340.00 | DKK 850.90 | 23 |
Feb ’24 | DKK 471.20 | DKK 475.37 +0.9% | 18.3% | DKK 600.00 | DKK 270.00 | DKK 786.40 | 23 |
Jan ’24 | DKK 469.00 | DKK 449.57 -4.1% | 15.4% | DKK 542.50 | DKK 270.00 | DKK 698.10 | 23 |
Dec ’23 | DKK 446.30 | DKK 436.25 -2.3% | 15.9% | DKK 542.50 | DKK 270.00 | DKK 698.70 | 24 |
Nov ’23 | DKK 400.50 | DKK 425.66 +6.3% | 15.6% | DKK 535.00 | DKK 270.00 | DKK 687.70 | 25 |
Oct ’23 | DKK 380.70 | DKK 418.04 +9.8% | 16.5% | DKK 512.50 | DKK 270.00 | DKK 643.90 | 26 |
Sep ’23 | DKK 386.65 | DKK 414.19 +7.1% | 16.3% | DKK 512.50 | DKK 270.00 | DKK 650.60 | 26 |
Aug ’23 | DKK 423.55 | DKK 413.73 -2.3% | 16.9% | DKK 512.50 | DKK 270.00 | DKK 550.10 | 26 |
Analyst Forecast: Target price is less than 20% higher than the current share price.